Evaluation of Chromosome 11p Imbalances in Aniridia and Wilms Tumor Patients

2013 ◽  
Vol 161 (5) ◽  
pp. 958-964 ◽  
Author(s):  
Maike Busch ◽  
Barbara Leube ◽  
Anne Thiel ◽  
Ina Schanze ◽  
Manfred Beier ◽  
...  
Keyword(s):  
Wilms Tumor ◽  
Tumor Patients ◽  
Chromosome 11P

scholarly journals Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: A report from the Children's Oncology Group

2018 ◽  
Vol 66 (1) ◽  
pp. e27430 ◽  
Author(s):  
Douglas S. M. Iaboni ◽  
Yueh-Yun Chi ◽  
Yeonil Kim ◽  
Jeffrey S. Dome ◽  
Conrad V. Fernandez
Keyword(s):  
Bone Metastasis ◽  
Wilms Tumor ◽  
Oncology Group ◽  
Tumor Patients ◽  
Tumor Studies

Renin-induced hypertension in Wilms tumor patients

2007 ◽  
Vol 48 (5) ◽  
pp. 500-503 ◽  
Author(s):  
M.H. Maas ◽  
K. Cransberg ◽  
M. van Grotel ◽  
R. Pieters ◽  
M.M. van den Heuvel-Eibrink
Keyword(s):  
Wilms Tumor ◽  
Tumor Patients ◽  
Induced Hypertension

Non-11p Constitutional Chromosome Abnormalities in Wilms' Tumor Patients

1995 ◽  
Vol 24 (5) ◽  
pp. 305-309 ◽  
Author(s):  
Jane M. Olson ◽  
Anne Hamilton ◽  
Norman E. Breslow
Keyword(s):  
Wilms Tumor ◽  
Chromosome Abnormalities ◽  
Tumor Patients

EP-1357: Dosimetric assessment of IMRT in total abdominal irradiation in Wilms tumor patients

2014 ◽  
Vol 111 ◽  
pp. S107
Author(s):  
M. Ramos Albiac ◽  
D. Mosquera ◽  
M. Hermida-López ◽  
J. Giralt
Keyword(s):  
Wilms Tumor ◽  
Tumor Patients ◽  
Dosimetric Assessment ◽  
Abdominal Irradiation

Kidney protein profiling of Wilms' tumor patients by analysis of formalin-fixed paraffin-embedded tissue samples

2014 ◽  
Vol 433 ◽  
pp. 235-241 ◽  
Author(s):  
Elke Hammer ◽  
Florian D. Ernst ◽  
Andrea Thiele ◽  
Narasimha Kumar Karanam ◽  
Christina Kujath ◽  
...  
Keyword(s):  
Wilms Tumor ◽  
Protein Profiling ◽  
Tumor Patients ◽  
Tissue Samples ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Formalin Fixed

scholarly journals Wilms Tumorigenesis in Human Kidney Organoids

2021 ◽  
Author(s):  
Verena Waehle ◽  
Rosemarie Ungricht ◽  
Philipp S. Hoppe ◽  
Joerg Betschinger
Keyword(s):  
Wilms Tumor ◽  
Human Kidney ◽  
Wild Type ◽  
Tumor Patients ◽  
Gene Expression Analyses ◽  
Cell Progression ◽  
Transcriptional Changes ◽  
Mutant Cells ◽  
Cancer In Children ◽  
Kidney Organoids

SUMMARYThe loss or failure of cell differentiation is a hallmark of cancer, yet whether perturbation of differentiation is causal or consequential to malignant transformation is largely unclear. Wilms tumor is the most widespread kidney cancer in children. Here, we establish a model for Wilms tumorigenesis in human kidney organoids. We show that loss of the tumor suppressor WT1 during organoid formation induces overgrowth of kidney progenitor cells at the expense of differentiating tubules. Functional and gene expression analyses demonstrate that absence of WT1 halts progenitor cell progression at a pre-epithelialized cell state and recapitulates the transcriptional changes detected in a subgroup of Wilms tumor patients with ectopic myogenesis. By “transplanting” WT1 mutant cells into wild-type kidney organoids, we find that their propagation requires an untransformed microenvironment. Genetic engineering of cancer lesions in human organoids therefore permits phenotypic modeling of tumor initiation and progression, and complements the current toolbox of pre-clinical Wilms tumor models.

scholarly journals A Pilot Study of Comprehensive Genomic Profiling for Pediatric and Adolescent and Young Adult Solid Tumor Patients in Japan

2021 ◽  
Author(s):  
Shotaro Matsudera ◽  
Yoshihito Kano ◽  
Yasuko Aoyagi ◽  
Kohki Tohyama ◽  
Kei Ogino ◽  
...  
Keyword(s):  
Solid Tumor ◽  
Wilms Tumor ◽  
Adolescent And Young Adult ◽  
Genomic Alteration ◽  
Genomic Profiling ◽  
Tumor Patients ◽  
Comprehensive Genomic Profiling ◽  
Healthcare Insurance ◽  
Tumor Types ◽  
Basket Trials

Background: Comprehensive genomic profiling (CGP) was widely adopted in Japan after its coverage by national healthcare insurance began in June 2019. We investigated the clinical utility of CGP in pediatric and adolescent young adults (AYA) solid tumor patients. Procedure: Between November 2017 and December 2019, 13 patients who progressed with or who were likely to progress with standard therapies were recruited to the PROFILE-F study to undergo CGP using either FoundationOne® CDx or FoundationOne® Heme. Results: The median age was 28 years old. Tumor types were as follows: neuroblastoma (n=1), Wilms’ tumor (n=1), rhabdomyosarcoma (n=2), Ewing sarcoma (n=1), gastric cancer (n=1), rectal cancer (n=1), osteosarcoma (n=1), neuroendocrine tumor (n=2), salivary gland carcinoma (n=1), tracheal adenoid cystic carcinoma (n=1), and thymic cancer (n=1). In 92% of cases, at least one genomic alteration was identified, including CDKN2A (four cases), TP53 (three cases), and MYC (two cases). Actionable aberrations were found in 10 cases (77%), and a clinical trial candidate was found in seven cases (54%). However, no patients were able to receive biomarker-matched therapy according to their genomic alterations. Conclusions: Further efforts to increase basket trials and collection of clinical genomic data to predict response are necessary to advance precision cancer medicine in pediatric and AYA populations.

#679 Regulation of NK activity by IL-2 in wilms tumor patients

1997 ◽  
Vol 19 (4) ◽  
pp. 397
Author(s):  
M. R. del Olmo ◽  
M. Alvarez de Món ◽  
B. Lopez-Ibor ◽  
M. J. Cilleruelo ◽  
I. Sánchez ◽  
...  
Keyword(s):  
Wilms Tumor ◽  
Nk Activity ◽  
Tumor Patients

Cardiac function in Wilms' tumor survivors.

1995 ◽  
Vol 13 (7) ◽  
pp. 1546-1556 ◽  
Author(s):  
K Sorensen ◽  
G Levitt ◽  
D Sebag-Montefiore ◽  
C Bull ◽  
I Sullivan
Keyword(s):  
Risk Factors ◽  
Cardiac Function ◽  
Cumulative Dose ◽  
Wilms Tumor ◽  
Dose Intensity ◽  
Normal Subjects ◽  
Left Ventricular ◽  
Tumor Patients

PURPOSE To study late cardiac function in a single diagnostic group (children with Wilms' tumor) with good long-term survival; to compare patients treated with anthracyclines (doxorubicin) with patients treated without anthracyclines and with a normal child/adolescent group; and to examine the risk factors involved in late cardiac dysfunction. PATIENTS AND METHODS Echocardiographic studies were performed on 97 Wilms' tumor patients treated with anthracyclines (mean cumulative dose, 303 mg/m2) with a mean follow-up time of 7.1 years, on 39 Wilms' tumor patients treated without anthracyclines with a mean follow-up time of 8.9 years, and on 50 normal subjects. Left ventricular (LV) dimensions, end systolic wall stress (a measure of afterload), and load-dependent and -independent measures of contractility were compared between groups. Potential risk factors, including age at diagnosis, follow-up duration, sex, pubertal status, cardiac irradiation, dose-intensity, and cumulative dose of anthracyclines, were studied by multivariate analysis. RESULTS Twenty-five percent of the anthracycline-treated group showed cardiac abnormalities. All but one of these patients had increased LV afterload. Risk factors for increased afterload were anthracycline cumulative dose (P < .05) and anthracycline dose-intensity (P < .02). Wilms' tumor patients treated without anthracyclines had thickened LV walls compared with normal subjects (P < .05). CONCLUSION Total dose and dose-intensity of anthracycline were risk factors for increased LV afterload in long-term Wilms' tumor survivors treated on standard protocols. The increase in afterload accounted for reduced LV shortening, whereas contractility was rarely abnormal. The new finding that Wilms' tumor survivors who do not receive anthracyclines have mild LV hypertrophy may provide some protection against anthracycline-induced cardiotoxic effects.

Sign in / Sign up

Export Citation Format

Share Document